CCR2 and neoplasm: What's more, after the treatment of FOLFIRINOX plus PF‐04136309, the mean ratio of blood to bone‐marrow CCR2+ monocytes in patients was significantly decreased compared with that in the FOLFIRINOX alone group (1.06 vs. 6.46), which indicated that FOLFIRINOX plus PF‐04136309 could prevent CCR2+ monocyte egress from the bone marrow to the peripheral blood and might affect the anti‐tumour immunity.170